Stahlman, Shauna
Beyrer, Chris
Sullivan, Patrick S.
Mayer, Kenneth H.
Baral, Stefan D.
Article History
First Online: 5 April 2016
Compliance with Ethical Standards
:
: This publication was made possible with help from the Johns Hopkins University Center for AIDS Research, an NIH funded Program (P30AI094189), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
: Chris Beyrer is receiving a donation of Tenofovir/Emtricitabine (Truvada) from Gilead, Inc. for an effectiveness study of a multi-level combination HIV preventive intervention with and without daily oral Truvada pre-exposure prophylaxis among young men who have sex with men in Bangkok, Thailand (R01AI118505; PI: Beyrer). Kenneth H. Mayer has received unrestricted research grants from Gilead Sciences and ViiV Healthcare. Shauna Stahlman, Patrick S. Sullivan, and Stefan D. Baral declare that they have no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
Free to read: This content has been made available to all.